www.黄在线看_国产成人午夜精品影院游乐网_国产成人久久av免费高清蜜臀_久久久999久久久_午夜 国产_一区二区三区四区国产

加入收藏 | 設為首頁 | 聯系我們

產品搜索

聯系我們

聯系人:蔣經理
電話:4008750250
號碼:
手機:18066071954
地址:南京市棲霞區緯地路9號
Email: zhangxiangwen@cobioer.com

產品展示 / PRODUCTS
藥靶細胞株 > kinase激酶細胞株 > CBP73205KIF5B(E15)-RET(E12)-Short/BaF3

KIF5B(E15)-RET(E12)-Short/BaF3
名稱 KIF5B(E15)-RET(E12)-Short/BaF3
型號 CBP73205
報價
特點 KIF5B(E15)-RET(E12)-Short/BaF3,母細胞:BaF3,凍存條件:90% FBS+10% DMSO
  • 詳細內容
CBP73205
I. Introduction

Cell Line Name:

KIF5B(E15)-RET(E12)-Short/BaF3

Host Cell:

Ba/F3

Stability:16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)

Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RPMI-1640+10%FBS+1 ug/ml puromycin

Mycoplasma Status:

Negative


II.Background

Chromosomal rearrangements involving the gene that encodes the RET tyrosine kinase are known oncogenic drivers in 1% to 2% of patients with non–small cell lung cancer (NSCLC). These RET rearrangements occur with characteristic partners, most commonly KIF5B, but also CCDC6, NCOA, TRIM33, CUX1, KIAA1217, FRMD4A, and KIAA1468. They are typically identified in young patients with adenocarcinoma histology and minimal smoking history. Therapeutic targeting of RET-fusion–driven NSCLCs has taken the form of treatment with broad-spectrum tyrosine kinase inhibitors with anti-RET activity, such as cabozantinib (Cabometyx; Cometriq), vandetanib (Caprelsa), lenvatinib (Lenvima), RXDX-105, and sunitinib (Sutent). Cabozantinib and vandetanib have been the most heavily studied multi-kinase inhibitors (MKIs), with response rates of 20% to 50% in largely pretreated patients with RET-rearranged NSCLC. Sunitinib has been used in fewer patients to date with initial results demonstrating a 22% response rate. RXDX-105 has exhibited uniquely impressive response rates (75%) in patients with non–KIF5B-RET-fusion NSCLC, compared with 0% response in patients with KIF5B-RET-fusion–positive NSCLC. BLU-667 has demonstrated an objective response rate of 50% in patients with RET-fusion positive NSCLC, and LOXO-292 reported a 74% ORR in patients with RET-fusion positive NSCLC. Notably, RXDX-105, BLU- 667, and LOXO-292 have all demonstrated some central nervous system activity in these early phase trials. Future directions of RET inhibition in patients with RET-rearranged NSCLC include additional clinical validation of the next generation RET-selective inhibitors RXDX-105, BLU-667, and LOXO-292 and comparing multikinase inhibitors with RET-selective inhibitors to determine the optimal sequencing of RET-targeted therapies.


III. Representative Data

1. WB of KIF5B-RET (K15, R12S)/BaF3

CBP73205 WB.jpg


2. Sanger of KIF5B-RET (K15, R12S)/BaF3

CBP73205 sanger1.png


CBP73205 sanger2.png


3. Anti-proliferation assay

CBP73205 fig.jpg

Figure 4. CTG Proliferation Assay of BaF3 KIF5B-Ret (s) Cells (C6).




如果你對CBP73205KIF5B(E15)-RET(E12)-Short/BaF3感興趣,想了解更詳細的產品信息,填寫下表直接與廠家聯系:


留言框

  • 產品:

  • 您的單位:

  • 您的姓名:

  • 聯系電話:

  • 常用郵箱:

  • 省份:

  • 詳細地址:

  • 補充說明:

  • 驗證碼:

    請輸入計算結果(填寫阿拉伯數字),如:三加四=7

化工儀器網

推薦收藏該企業網站
主站蜘蛛池模板: 亚洲一卡2卡三卡4卡无卡下载 | 午夜精品久久久久久久四虎 | 午夜免费片 | 夜夜揉揉日日人人青青 | 99久久国语露脸精品国产 | sis色中色| 精品无码一区二区三区在线 | 午夜精品久视频在线观看 | 日本花心黑人hd捆绑 | 日本人成在线视频免费播放 | 精品国产午夜理论片不卡 | 国产精品欧美韩国日本久久 | 九九九色视频在线观看免费 | 香港三日本三级少妇三级视频 | 国产人成亚洲第一网站在线播放 | 丰满熟女人妻中文字幕免费 | 久久久国产这里有的是精品 | 福利视频二区 | 欧美日韩国产综合草草 | 网禁拗女稀缺资源在线观看 | 国产真实伦视频在线观看 | 两个人看的www高清视频 | 久久久久女人爽女人爽 | 99久热只有精品视频免费看 | 精品亚洲一区二区三区 | 国产亚洲欧美日韩俺去了 | 粉嫩国产15xxxxx | 女人一级特纯黄大片色 | h片免费在线观看 | 日韩美女性行为免费视频 | 亚洲国产精品无码久久一线 | 亚洲欧美成人永久第一网站 | 久久综合av色老头免费观看 | 国产日韩欧美视频在线 | 少妇人妻精品一区二区 | 色久悠悠在线 | 公车忘穿内裤被挺进小说 | 日韩中文字幕电影 | 四虎网站在线观看 | 久久夜色精品国产亚洲av | 97免费人妻无码视频 |